

1 **Nasal-Swab Testing Misses Patients**
2 **with Low SARS-CoV-2 Viral Loads**

3 Cody Callahan^a, Rose A. Lee^{b,c,d}, Ghee Rye Lee^e, Kate Zulauf,^{b,d}
4 James E. Kirby,^{b,d} and Ramy Arnaout^{b,d,f,#}

5 ^aDepartment of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA 02215

6 ^bDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

7 ^cDivision of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical
8 Center, Boston, MA, USA

9 ^dHarvard Medical School, Boston, MA, USA

10 ^eDepartment of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA 02215

11 ^fDivision of Clinical Informatics, Department of Medicine, Beth Israel Deaconess Medical Center,
12 Boston, MA USA 02215

13 [#]To whom correspondence should be addressed at

14 Ramy Arnaout, MD, DPhil
15 Beth Israel Deaconess Medical Center
16 330 Brookline Avenue—YA309
17 Boston, MA 02215
18 rarnaout@bidmc.harvard.edu
19 617-667-3648

20 **Abstract**

21 The urgent need for large-scale diagnostic testing for SARS-CoV-2 has prompted pursuit of
22 sample-collection methods of sufficient sensitivity to replace sampling of the nasopharynx (NP).
23 Among these alternatives is collection of nasal-swab samples, which can be performed by the
24 patient, avoiding the need for healthcare personnel and personal protective equipment.
25 Previous studies have reached opposing conclusions regarding whether nasal sampling is
26 concordant or discordant with NP. To resolve this disagreement, we compared nasal and NP
27 specimens collected by healthcare workers in a cohort consisting of individuals clinically
28 suspected of COVID-19 and outpatients known to be SARS-CoV-2 RT-PCR positive undergoing
29 follow-up. We investigated three different transport conditions, including traditional viral
30 transport media (VTM) and dry swabs, for each of two different nasal-swab collection protocols
31 on a total of 308 study participants, and compared categorical results and Ct values to those
32 from standard NP swabs collected at the same time from the same patients. All testing was
33 performed by RT-PCR on the Abbott SARS-CoV-2 RealTime EUA (limit of detection [LoD], 100
34 copies viral genomic RNA/mL transport medium). We found high concordance (Cohen's kappa
35 >0.8) only for patients with viral loads above 1,000 copies/mL. Those with viral loads below
36 1,000 copies/mL, the majority in our cohort, exhibited low concordance (Cohen's kappa = 0.49);
37 most of these would have been missed by nasal testing alone. Previous reports of high
38 concordance may have resulted from use of assays with higher LoD ($\geq 1,000$ copies/mL). These
39 findings counsel caution in use of nasal testing in healthcare settings and contact-tracing efforts,
40 as opposed to screening of asymptomatic, low-prevalence, low-risk populations. Nasal testing is
41 an adjunct, not a replacement, for NP.

42 **Introduction**

43 Controlling the COVID-19 pandemic will require a massive expansion of testing for SARS-CoV-
44 2 in several different clinical and epidemiological contexts. Until recently, nasopharyngeal (NP)
45 swabs were the United States Centers for Disease Control and Prevention's (CDC) preferred
46 specimen type, as these specimens were thought to provide the most robust detection of patient
47 infection. However, there are conflicting reports as to which of several specimen types bear the
48 highest viral load¹⁻³, and ultimately the "preferred-specimen" specification was removed from
49 interim CDC guidance on 29 April 2020⁴. Sensitivity is a complex issue, however, as detection in
50 the upper airways (nasopharynx and oropharynx) is affected by multiple factors including

51 duration of illness prior to testing⁵ as well as the limit of detection (LoD) of the RT-PCR assay
52 used⁶.

53 Availability of NP swabs and the resources to establish NP collection sites with specimen
54 collection personnel have remained critical bottlenecks. To resolve these issues, healthcare
55 systems have adopted multiple different strategies, including engaging industrial manufacturers
56 to mass produce novel 3D-printed NP swabs⁷, as well as evaluating different specimen types
57 and alternative sample-collection strategies⁸⁻¹⁶. Assessment of nasal swabs is a rapidly growing
58 area of interest, specifically because this specimen type involves a less invasive procedure than
59 NP swabs, as only the anterior-to-mid-turbinate area of the nasal passages is accessed.
60 Accordingly, such samples can be self-collected by patients with a simple set of instructions,
61 alleviating the need for highly trained medical personnel for specimen collection and reducing
62 use of personal protective equipment (PPE) in short supply.

63 Many of the US Food and Drug Administration Emergency Use Authorization (FDA EUA) RT-
64 PCR assays have approval for use of nasal swabs as a specimen type, but how well nasal
65 swabs perform compared to NP swabs remains unclear. To date, nasal-swab studies have
66 shown conflicting results, with some researchers reporting similar test performance to NP swabs
67 and others finding decreased sensitivity^{8,10,12-16}. Reconciling these differences is challenging, as
68 these studies employed different sampling materials, collection methods, and RT-PCR assays.
69 To address these conflicting reports, here we describe results of a six-arm, 308-subject study
70 comparing two different healthcare-worker nasal-swab collection procedures and three different
71 transport conditions, including in viral transport media (VTM) and dry transport. We discuss our
72 findings in the context of prior reports (including preprints), to more systematically assess nasal-
73 swab test performance and its potential role(s) in addressing diagnostic and epidemiologic
74 needs in the COVID-19 pandemic.

75 **Materials and Methods**

76 **Trial design.** Participants were adults over 18 years of age tested for SARS-CoV-2 during the
77 normal course of clinical care, based either on clinically suspected COVID-19 infection or follow-
78 up after previous SARS-CoV-2-positive RT-PCR testing. Participants were asked to be
79 swabbed twice, first with one of the nasal swabs under study (see below for swab-collection
80 protocols) and then with a standard NP swab. To control for potential variability related to self-
81 swabbing, sample collection was performed by trained nurses or respiratory-therapy staff

82 ("study staff") with training and oversight from the respiratory therapy department at Beth Israel
83 Deaconess Medical Center (BIDMC) drive-through/walk-up ("drive-through") COVID-19 testing
84 sites. Individuals with known thrombocytopenia (<50,000 platelets/ μ l) were excluded from the
85 study to avoid risk of bleeding. This study was reviewed and approved by BIDMC's institutional
86 review board (IRB protocol no. 2020P000451).

87 **Transport conditions and swabs used.** Standard nasal swabs were compared under three
88 different specimen-transport conditions: (i) a guanidine thiocyanate (GITC) transport buffer, part
89 of the Abbott multi-Collect Specimen Collection Kit, catalog no. 09K12-004; Abbott Laboratories,
90 Abbott Park, IL), (ii) dry, with no buffer; and (iii) in modified CDC viral transport media (VTM)
91 (Hank's balanced salt solution containing 2% heat inactivated FBS, 100 μ g/mL gentamicin,
92 0.5 μ g/mL fungizone, and 10mg/L Phenol red, produced by the Beth Israel Deaconess Medical
93 Center [BIDMC] Clinical Microbiology Laboratories¹⁷). The nasal swab used was the included
94 Abbot swab for the GITC arm and the Hologic Aptima Multitest Swab otherwise (catalog no.
95 AW-14334-001-003; Hologic Inc. Marlborough, MA). The NP swab used was the Copan BD
96 ESwab collection and transport system swab (catalog no. 220532; Copan Diagnostics Inc.,
97 Murietta, CA).

98 **PCR compatibility.** Although all swabs are routinely used for PCR testing, as a double-check
99 each swab type was assessed for PCR compatibility by overnight incubation in 3 mL of modified
100 CDC VTM (allowing potential PCR inhibitors time to leech into media), spiking 1.5 mL of media
101 with 200 copies/mL of control SARS-CoV-2 amplicon target (twice the LoD of our system),
102 vortexed, and tested using the Abbott RealTime SARS-CoV-2 Assay on an Abbott m2000
103 RealTime System platform¹⁸, the assay and platform used for all testing in this report, following
104 the same protocol used for clinical testing (see below). All swabs examined in this study passed
105 this quality-control testing for lack of RT-PCR inhibition based on observation of Ct values within
106 expected quality control limits¹⁷.

107 **Swab collection protocols (Fig. 1).** For Procedure 1, for each naris, the swab tip was inserted
108 into the nostril, the patient was told to press a finger against the exterior of that naris, and the
109 swab was rotated against this external pressure for 10 seconds (Fig. 1a); this procedure was
110 repeated with the same swab on the other naris, and then the swab was placed into the
111 collection tube for transport to the laboratory for testing. For Procedure 2, the swab was inserted
112 into the naris until resistance was felt, and the swab was then rotated for 15 seconds without
113 external pressure (Fig. 1b); this procedure was repeated with the same swab on the other naris,

114 and the swab was then placed into the collection tube for transport¹⁵. The NP-swab sample was
115 collected from a single naris by standard technique: insertion to appropriate depth, 10 rotations,
116 removal, and placement into transport-media tube containing VTM⁴. To maximize collection of
117 material from the nares, in all cases sampling using the nasal swab (both nares) was performed
118 first, before the NP swab.

119 **Sample processing and testing.** Samples were sent to the BIDMC Clinical Microbiology
120 Laboratories for testing. Dry swabs were eluted in 2mL of Abbott *mWash1* (100mM Tris with
121 guanidinium isothiocyanate (GITC) and detergent). Swabs transported in GITC buffer were
122 supplemented with 1mL of Abbott *mWash1* solution to achieve minimum volume requirements
123 for testing. Tests were performed with 1.5mL of sample media using the Abbott RealTime
124 SARS-CoV-2 assay for EUA for use with nasopharyngeal and nasal swabs¹⁸. This dual-target
125 assay detects both the SARS-CoV-2 RdRp (RNA-dependent RNA polymerase) and N
126 (nucleocapsid) genes with an in-lab verified LoD of 100 copies/mL^{6,17}.

127 **Statistical analyses.** RT-PCR results reported categorically as either positive or negative, and
128 these were used for concordance testing by Cohen's kappa¹⁹.

129 For analyses based on cycle-threshold (Ct) values, for discordant samples (positive nasal-
130 swab/negative NP-swab result or vice versa), the negative result was assigned a Ct value of 37,
131 the total number of cycles run. Conversion to viral load was performed as described previously⁶.

132 We tested whether Ct values for a given set of nasal swabs differed from the Ct values for the
133 paired NP swabs (the controls) using Wilcoxon's paired *t*-test. This tested the null hypothesis
134 that values for controls and prototypes are drawn from the same underlying distribution; $p > 0.05$
135 was interpreted as no difference. We used bootstrapping to test whether the *n* results for a
136 given arm exhibited appreciable differences from others, specifically by testing whether a given
137 arm differed from random samples from (*i*) results pooled across the three arms that used the
138 same nasal-swab sampling procedure or (*ii*) all results. For each bootstrap test, we sampled *n*
139 data points at random from the larger pool to create a synthetic dataset, calculating Cohen's
140 kappa on this synthetic dataset, and repeating this process for 100,000 synthetic datasets to
141 create a distribution (histogram) of kappa values; this distribution constitutes a null model of the
142 kappa one would expect to observe by chance in a sample of *n* results, given the data in the
143 larger pool. Using this distribution, we then calculated the probability of observing a kappa at
144 least as high as the kappa actually observed for the *n* results from a given arm, to test for

145 consistency with expectation; inconsistency ($p < 0.05$ or $p > 0.95$) would reject the null hypothesis
146 that the study arm and the larger pool are statistically indistinguishable (as measured by kappa).
147 For completeness, we performed the same bootstrap analysis to compare Procedure 1 results
148 to all results and to compare Procedure 2 results to all results.

149 We used Python (v3.6-3.8) and its NumPy, SciPy, Matplotlib, Pandas, and ct2vi libraries for the
150 above analyses and related visualizations.

151 **Literature review.** We searched Pubmed and the preprint servers bioRxiv and medRxiv
152 through June 1, 2020 for all literature on nasal-swab sampling for SARS-CoV-2 and extracted
153 sample sizes, collection methods, RT-PCR assay information, and 2x2 contingency table data
154 comparing nasal swabs to NP swabs wherever available.

155 **Results**

156 Table 1 shows the numbers of patients tested in each of the six arms of our nasal- vs. NP-swab
157 study. Visual inspection of plots of the Ct values of the nasal swab vs. NP-swab controls
158 suggested worse performance for nasal swabs across all six arms, with no obvious differences
159 between the two swab procedures or among the dry-swab, VTM, or GITC collection methods
160 (Fig. 2). Statistical testing confirmed that results for each arm were indistinguishable from the
161 overall results, supporting the functional equivalence of all swab/transport-condition
162 combinations (Table 2). For concordant positives, comparison of Ct values between nasal and
163 NP swabs showed higher Cts for nasal swabs than for NP swabs, suggesting slightly but
164 consistently lower yield from the nasal swabs (Wilcoxon $p = 9 \times 10^{-11}$). Consistent with this
165 conclusion, there was a marked increase in false negatives for NP-swabs with higher Ct values
166 (lower viral loads), resulting in low concordance overall (Cohen's kappa=0.49) (Fig. 2).

167 Our overall finding of low concordance was in contrast to some previous reports, which have
168 found nasal-swab collection to exhibit excellent sensitivity as well as Ct-value concordance^{13,15},
169 but was consistent with others^{10,14}, including, for example, one recent study at a New York,
170 USA, hospital that also noted lower nasal-swab concordance for higher Ct values¹⁶. Close
171 review of these previous reports revealed that they differed in the type of specimen and/or result
172 they used as a reference (e.g. any test-sample positive versus using NP swabs as the gold
173 standard) and in the parameters they used in order to describe test performance (e.g. positive
174 percent agreement versus sensitivity). To control for at least the latter, we extracted 2x2

175 contingency-table data from these reports to facilitate comparison to each other and to our own
176 results (Table 3). Notably, many of these studies used a modified version of the CDC assay that
177 did not report a LoD. Furthermore, of the studies that report the Ct values of their results, no
178 viral-load conversion was provided, which is important since different RT-PCR assays and
179 platforms have unique conversions between Ct value and viral load. Therefore, we were unable
180 to systematically compare nasal-swab performance at low viral loads in these reports. These
181 differences left open the possibility that inconsistent comparative performance of nasal-swab
182 sampling might be explained largely by differences assay LoD, and possibly also by patient viral
183 load. (We note that while the nasal-swab sampling protocols and transport media conditions
184 varied between studies, our results suggest these differences are unlikely to affect detection).

185 We therefore revisited the trend we observed of a rise in nasal-swab-negative discordant results
186 (false negatives) with higher Ct value. Recently we demonstrated that Ct values for the SARS-
187 CoV-2 RT-PCR assay and platform used in the present study are reliable quantitative measures
188 of viral load, and introduced a conversion from Ct value to viral load⁶. Building on those findings,
189 here we asked what the concordance would have been, for our nasal-vs.-NP data, had the LoD
190 of our assay been higher than its actual 100 copies/mL. Specifically, we re-calculated kappa for
191 different LoD cutoffs, and found that kappa rose steeply from ~0.5 (low concordance) to 0.8-0.9
192 (excellent concordance) as the LoD cutoff was increased from 100 copies/mL through 1,000
193 copies/mL and beyond (Fig. 3). This finding strongly supports the view that nasal swabs miss
194 many if not most patients with low viral load (below ~1,000 copies/mL), but is reliable for
195 patients with medium or high viral loads, potentially resolving disagreements among previous
196 reports.

197 **Discussion**

198 It is widely acknowledged that resolving the damage that the COVID-19 pandemic has wrought
199 to health, the economy, and society will require distributing and scaling up testing to
200 unprecedented levels. For this reason, there is great and widespread interest in developing
201 alternatives to NP-swab sampling for COVID-19 diagnosis. Governments and medical
202 institutions alike have expressed interest in adopting nasal swabs as an alternative, as the self-
203 administration of these swabs would allow vastly increased testing capacity, save PPE, and
204 ease the burden on healthcare workers. Independently, the ability to transport swabs to testing
205 locations without need of transport media such as VTM would further streamline testing

206 processes. Reflecting this interest in nasal swabs, the US CDC has removed the “preference”
207 specification for NP swabs from their interim guidance and note that nasal swabs are an
208 acceptable alternative specimen as of 29 April 2020⁴. However, confidence in population-scale
209 testing strategies based on nasal swabs is complicated by conflicting reports as to how well they
210 perform relative NP swabs, the antecedent gold standard, as we have described.

211 Our results strongly suggest that concordance between nasal and NP swabs depends on the
212 LoD of the PCR assay used to measure positivity, with high concordance for medium-to-high
213 viral loads and low concordance for low viral loads, which may lie below the LoDs of various
214 assays currently in widespread use (Fig. 3)⁶. We find that nasal swab samples reliably detect
215 patients with viral loads $\geq 1,000$ copies/mL but miss many patients who have lower viral loads,
216 the majority in our study⁶. A complete biological explanation will require further study; however,
217 one possibility is that in cases of high viral load, replicating virus may be more likely to spread to
218 respiratory epithelium bordering and/or in the deeper portions of the anterior nares, where it can
219 be recovered by nasal swab.

220 our findings may reconcile disagreements in prior reports, which have compared nasal swab
221 performance only as a function of Ct values which are not comparable from study to study, not
222 viral load, as we have done here. We hypothesize that the outpatient/urgent care testing sites
223 in these studies may have selected for patients early in the course of disease, when viral load is
224 high^{13,15}. For example, one study¹³ that showed high concordance used an assay with a
225 negative Ct cutoff of 40, and only a handful of patient samples had Ct values above 35.
226 Although again the viral loads were not reported, the discrepancy between cutoff and Ct values
227 suggested preferential sampling of patients with only high viral loads. (Note that a Ct value of 35
228 can correspond to different viral loads in different assays and the LoD of this assay was 4,167
229 copies/mL, over 40 times the cutoff in the assay we used.) Notably, the patient population in the
230 present study consisted of both first-time and individuals with repeat testing for test of cure.
231 Many of the latter have been observed to exhibit low-level viral load for multiple weeks in the
232 absence of severe symptoms and enrichment of these patients may impact the overall
233 performance of NP and nasal swabs in individual studies. In other studies, such differences may
234 be more or less obscured depending on the limit of detection of the assay in use which may
235 straddle the 1,000 copies/mL threshold we found for nasal swabs to consistently detect
236 infection.

237 Interestingly, we found no difference among transport media conditions and between sampling
238 protocols, suggesting that lower sensitivity of nasal swab sampling is an overall limitation of the
239 anatomical location of nasal swabs and that the protocols and media conditions we tested are
240 interchangeable. Thus, for patients above a critical threshold of 1,000 copies/mL (Fig. 2), nasal
241 swabs collected in VTM, GITC transport medium, and as dry swabs are all likely to perform
242 equally well in the population, providing multiple potential options for specimen acquisition.

243 Our results suggest several settings in which nasal swabs may and may not best be used. Peak
244 infectiousness is likely to occur near or shortly before symptom onset^{20,21} and nasopharyngeal
245 viral load is often undetectable a week after symptom onset². Lower-sensitivity testing would
246 therefore likely miss patients with early developing presymptomatic infections and patients
247 presenting multiple days after symptom onset. Notably, for those presenting later to care, a
248 false-negative diagnosis could bear significant clinical implications in not only erroneously
249 reassuring the patient and clinical team, but also excluding them from potentially useful and
250 rationed therapies such as remdesivir²² or others. Importantly, based on viral load distribution in
251 first-time tested individuals at our institution, ~20% of newly presenting SARS-CoV-2 positive
252 individuals would be missed if sampled solely using nasal swabs⁶, highlighting the potential
253 magnitude of this problem.

254 Nevertheless, nasal swabs provide considerable advantage in terms of ease of collection and
255 potential self-collection. Based on our results, they would serve best in high-test-volume, point
256 prevalence screens in healthy populations, for example, in businesses and universities, where
257 identification of highly infectious individuals will be a prelude to targeted testing with the most
258 sensitive techniques possible to quell outbreaks and forestall local spread. Conversely, nasal
259 swabs should not be used for screening symptomatic and especially hospitalized patients,
260 where the more sensitive and resource intensive nasopharyngeal sampling would be justified,
261 and help direct care and most appropriate use of infection control resources. In summary, whilst
262 nasal swabs are a welcome addition to the armamentarium of tools needed to combat COVID-
263 19, we should be well aware of possible limitations in diagnostic sensitivity and use this
264 resource judiciously.

265 **Acknowledgements**

266 The authors would like to acknowledge Dr. Yuan-Po Tu for graciously sharing his nasal swab
267 protocol and Susan E. Devito, Kelly Gibbs, Angela E. Martignetti, Nancy R. Sheridan, Carl A.

268 Santiago, Erin Martin, Erin K. Martin, Janet Mulvey, Mallory Flynn, Shannon Healy, Lauren
269 Kennedy, Jill Lococo, Jose A. Abrego, Tracy Flynn, Jean M. Pietrantonio, Kelina Orlando, Carol
270 Daugherty, (Carl) Adrian Santiago, Ann Marie Zampitella, Scott Hamelin, Maria Ortega, Frantzia
271 Clermont, April Gagnon, Elvia Pires Barbosa Fernandes, Brenda Pinto, Brittany
272 Williamson, Mairie Taline Dorcely, Sheila Moriarty, Kathy Corley, and Paula Stering for their
273 assistance in conducting this study.

274 Abbott multi-Collect Specimen Collection Kits were a generous gift of Abbott Laboratories.

275 K.E.Z. was supported by a National Institute of Allergy and Infectious Diseases training grant
276 (T32AI007061).

277 This work was conducted with support from The Harvard Clinical and Translational Science
278 Center (National Center for Advancing Translational Sciences, National Institutes of Health
279 Award UL 1TR002541) and financial contributions from Harvard University and its affiliated
280 academic healthcare centers. The content is solely the responsibility of the authors and does
281 not necessarily represent the official views of Harvard Catalyst, Harvard University and its
282 affiliated academic healthcare centers, or the National Institutes of Health.

283

Tables and Figures

284

Table 1: Number of specimens by study arm

Collection method	Transportation conditions		
	GITC	Dry	VTM
Procedure 1	47 (1)	36 (2)	39 (3)
Procedure 2	65 (4)	61 (5)	60 (6)

285

Procedures 1 and 2 as in Methods and Fig. 1. Numbers in parentheses indicate study arms.

Table 2: Comparability of study arms and subsets

Comparison	p-value
Arm (1) vs. all Procedure 1	0.11
Arm (2) vs. all Procedure 1	0.85
Arm (3) vs. all Procedure 1	0.62
Arm (4) vs. all Procedure 2	0.78
Arm (5) vs. all Procedure 2	0.30
Arm (6) vs. all Procedure 2	0.53
Arm (1) vs. total	0.27
Arm (2) vs. total	0.82
Arm (3) vs. total	0.62
Arm (4) vs. total	0.71
Arm (5) vs. total	0.23
Arm (6) vs. total	0.44
Procedure 1 vs. total	0.66
Procedure 2 vs. total	0.29

287 Listed are p -value for bootstrap comparison of linear-regression fits of Ct values of nasal swab
288 vs. NP swab for observed samples for arms 1-6 from Table 1 vs. 10,000 random samples of
289 either Procedure 1 (top three rows), Procedure 2 (next three rows), total (next six rows). Bottom
290 two rows are bootstrap comparisons of all Procedure 1 (i.e., arms 1-3) to total and Procedure 2
291 (arms 4-6) to total. All comparisons show $p > 0.05$, interpreted as no significant differences
292 among arms and procedures.

293

Table 3: Comparison of nasal swab studies to date including their collection protocol and RT-PCR assay

Study	Samples	Collection Method	Nasal + NP +	Nasal + NP -	Nasal - NP +	Nasal - NP -	Kappa	RT-PCR method (LOD in copies/mL)
Berenger et al. (preprint)	36 previously positive patients tested an average of 4d prior	APTIMA Unisex Collection kit (Hologic Inc.) used to swab both nares to a depth of at least 3 cm (or until resistance felt) and rotated 3 times	22	2	5	7	0.53	Alberta Public Health Laboratory (Provlab) (LOD: 200 copies/mL)
Minich et al. (preprint)	10 patients admitted with COVID-19 verified by NP swab	Sterile polyester head, plastic shaft dry swab inserted into one nostril to a depth of ~2-3cm and rotated for 5-10 seconds. Then placed in collection tube containing 0.5 – 1mL 95% ethanol and stored on dry ice	3	0*	0**	1	1.00†	CDC protocol adaptation: 4µl RNA template, 100r 200nm probe, 3µl TaqPath, and water to a 10µl r Bio257 rad CFX384 Touch Real-Time PCR Detectic
			3	0*	1	2	0.66	
			Non-sterile cotton head, plastic shaft dry swab, same protocol as above	4	1	1**	1	
Wehrhahn et al.	236 Australian patients tested at outpatient locations	Nasal swabs were inserted as far as comfortably possible and at least 2-3 cm inside one nostril, rotating the swab 5 times and leaving in place for 5-10 seconds.	17	0	0	219	1.00†	Allplex™ 2019-nCoV Assay (Seegene, Seoul, South Korea) RT-PCR Detection Systems (no LOD listed)
Kojima et al. (preprint)	45 adults that were recently tested for SARS-CoV-2 via standard NP swab testing	Supervised self-collected nasal swab used a CLASSIQSwab™ that the patient was instructed to insert into one nostril to the depth of 3-4cm and rotate for 5-10 seconds before storing the swab in RNA storage media (DNA/RNA Shield, Zymo Research Corp)	19	4	4****	16	0.63	Modified CDC assay with addition of N3 target to run on CFX 96™ Touch or Connect Detection Syst
Tu et al. (preprint)	498 individuals tested at 5 different ambulatory centers	Nasal swabs collected with a foam swab (Puritan 25-1506 1PF100) via inserting in the vertical position into one nasal passage until gentle resistance and leaving the swab in place for 10-15 seconds and rotating. Swabs were stored in viral transport media.	47	1	3	447	0.96	Quest Diagnostics SARS-CoV-2 RNA, Qualitative R Capistrano, CA) targeting N1 and N3 (nucleocapsid protein) using RT-PCR
		Mid-turbinate swabs collected with a nylon flocced swab (MDL NasoSwab A36ZCS02) via inserting in the horizontal position into the nasal passage until gentle resistance is met, leaving the swab in for 10-15 seconds and rotating	50	2	0	452	0.98	
Basu et al. (preprint)	31 nasal swabs tested out of 101 samples collected in an adult ED	Dry nasal samples were obtained with swabs supplied with the Abbott assay (Puritan Medical Products 25-1506 1PF100). Nasal samples were obtained from both nares.	17	1	14	69	0.61	Abbott ID NOW (LOD 125 genome equivalents)/m Cepheid Xpert Xpress SARS-CoV-2 test (LOD: 250 copies/mL)

294

*1 nasal swab was inconclusive, while NP swab was negative, **1 nasal swab was inconclusive, while NP swab positive, ****2

295


samples were negative due to quantity insufficient. †Undependable given the zeros.

296

Figure 1: Nasal swabbing instructions

a


1. As reasonably needed, tilt the patient's head back to improve access to the anterior nares. For each naris (nostril), perform following.
2. Insert the swab tip into the nostril and press against the inner wall of the naris.
3. Press against the exterior naris, so that you may feel the pressure applied by the swab against your finger.
4. Rotate the swab for **10 seconds**, against the pressure of your finger (clockwise, counterclockwise, or both).
5. Remove swab from first naris and **repeat on the opposite naris**.
6. After thoroughly swabbing each naris, place swab into the appropriate tube.



297

b

1. Insert the swab horizontally into the first nostril until you meet resistance. **The entire length of the bulb should be completely inside the nose. This might make the participant feel like sneezing; reposition if necessary.**
2. **Twirl** the swab around for a full **15 seconds** in the first nostril.
3. Remove the swab from the first nostril and then insert **the same swab** horizontally into the second nostril, again until you meet resistance. **Again, the entire length of the bulb should be completely inside the nose.**
4. **Twirl** the swab around for a full **15 seconds** in the second nostril.
5. Remove swab from nose, place swab into the appropriate tube, and **seal the tube tightly.**




298

(a), Procedure 1; (b), Procedure 2. Procedure 2 was adapted from the trial of Tu et al¹⁵ . .

299


Figure 2: Comparisons of nasal-swab specimens to NP-swab controls



300

301 (a) Procedure 1; (b) Procedure 2; (c) total. Negatives are plotted with a Ct value of 37
 302 (maximum cycle no.): vertically stacked data points at the far right of the plots (x-axis value
 303 37) are false negatives, while data points at the top of the plots (y-axis value = 37) are false
 304 positives. Legend: study-arm numbers are the same as in Tables 1 and 2. κ , Cohen's kappa

305 **Figure 3: Low vs. high concordance depends on low vs. high assay sensitivity**



306

307 Concordance (measured by Cohen's kappa) plotted against assay LoD. With LoD of 100
308 copies/mL (yellow arrowhead) the Abbott assay detects false negatives in nasal-swab samples,
309 resulting in low concordance (0.49; yellow dotted line). An assay with LoD of 1,000 copies/mL
310 (blue arrowhead) would have missed these false negatives, which would have yielded a high
311 observed concordance (0.82; blue dotted line).

312 References

- 313 1 Yang Y, Yang M, Shen C, *et al.* Evaluating the accuracy of different respiratory specimens in
314 the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. *medRxiv*
315 2020; : 2020.02.11.20021493.
- 316 2 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients
317 with COVID-2019. *Nature* 2020; **581**: 465–9.
- 318 3 Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than
319 nasopharyngeal swabs | medRxiv.
320 <https://www.medrxiv.org/content/10.1101/2020.04.16.20067835v1> (accessed June 9, 2020).
- 321 4 CDC. Information for Laboratories about Coronavirus (COVID-19). Cent. Dis. Control Prev.
322 2020; published online Feb 11. [https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)
323 [clinical-specimens.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html) (accessed June 10, 2020).
- 324 5 Huang J-T, Ran R-X, Lv Z-H, *et al.* Chronological Changes of Viral Shedding in Adult
325 Inpatients with COVID-19 in Wuhan, China. *Clin Infect Dis* DOI:10.1093/cid/ciaa631.
- 326 6 Arnaout R, Lee RA, Lee GR, *et al.* SARS-CoV2 Testing: The Limit of Detection Matters.
327 *bioRxiv* 2020; : 2020.06.02.131144.
- 328 7 Callahan CJ, Lee R, Zulauf KE, *et al.* Open Development and Clinical Validation Of Multiple
329 3D-Printed Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19
330 Testing Bottleneck. *J Clin Microbiol* 2020; : JCM.00876-20, jcm;JCM.00876-20v1.
- 331 8 LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. A combined
332 oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection
333 of SARS-CoV-2. *J Clin Virol* 2020; **128**: 104442.
- 334 9 Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of
335 Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-
336 CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. *J*
337 *Clin Microbiol* 2020; : JCM.00760-20, jcm;JCM.00760-20v1.
- 338 10 Minich JJ, Ali F, Marotz C, *et al.* Feasibility of SARS-CoV-2 virus detection from consumer-
339 grade cotton swabs. *medRxiv* 2020; : 2020.05.12.20073577.

- 340 11 McCormick-Baw C, Morgan K, Gaffney D, *et al.* Saliva as an Alternate Specimen Source for
341 Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-
342 2. *J Clin Microbiol* 2020; : JCM.01109-20, jcm;JCM.01109-20v1.
- 343 12 Kojima N, Turner F, Slepnev V, *et al.* Self-Collected Oral Fluid and Nasal Swabs
344 Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-
345 19 Detection. *medRxiv* 2020; : 2020.04.11.20062372.
- 346 13 Wehrhahn MC, Robson J, Brown S, *et al.* Self-collection: An appropriate alternative during
347 the SARS-CoV-2 pandemic. *J Clin Virol* 2020; **128**: 104417.
- 348 14 Berenger BM, Fonseca K, Schneider AR, Hu J, Zelyas N. Sensitivity of Nasopharyngeal,
349 Nasal and Throat Swab for the Detection of SARS-CoV-2. *medRxiv* 2020; :
350 2020.05.05.20084889.
- 351 15 Tu Y-P, Jennings R, Hart B, *et al.* Swabs Collected by Patients or Health Care Workers for
352 SARS-CoV-2 Testing. *N Engl J Med* 2020; **0**. DOI:10.1056/NEJMc2016321.
- 353 16 Basu A, Zinger T, Inglima K, *et al.* Performance of the rapid Nucleic Acid Amplification by
354 Abbott ID NOW COVID-19 in nasopharyngeal swabs transported in viral media and dry nasal
355 swabs, in a New York City academic institution. *bioRxiv* 2020; : 2020.05.11.089896.
- 356 17 Smith KP, Cheng A, Chopelas A, *et al.* Large-scale, in-house production of viral transport
357 media to support SARS-CoV-2 PCR testing in a multi-hospital healthcare network during the
358 COVID-19 pandemic. *J Clin Microbiol* 2020; published online May 13.
359 DOI:10.1128/JCM.00913-20.
- 360 18 Anonymous. Abbott RealTime SARS-CoV-2 Emergency Use Authorization Package Insert.
361 REF 09N77-095, 51-608445/R1. <https://www.fda.gov/media/136258/download> (accessed
362 June 8, 2020).
- 363 19 McHugh ML. Interrater reliability: the kappa statistic. *Biochem Medica* 2012; **22**: 276–82.
- 364 20 He X, Lau EHY, Wu P, *et al.* Temporal dynamics in viral shedding and transmissibility of
365 COVID-19. *Nat Med* 2020; **26**: 672–5.
- 366 21 Arons MM, Hatfield KM, Reddy SC, *et al.* Presymptomatic SARS-CoV-2 Infections and
367 Transmission in a Skilled Nursing Facility. *N Engl J Med* 2020; **382**: 2081–90.

368 22Wang Y, Zhang D, Du G, *et al.* Remdesivir in adults with severe COVID-19: a randomised,
369 double-blind, placebo-controlled, multicentre trial. *The Lancet* 2020; **395**: 1569–78.

370